25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Celltrion Pharm Inc
Buy, Hold or Sell?

Let's analyze Celltrion Pharm Inc together

I guess you are interested in Celltrion Pharm Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Celltrion Pharm Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Celltrion Pharm Inc

I send you an email if I find something interesting about Celltrion Pharm Inc.

1. Quick Overview

1.1. Quick analysis of Celltrion Pharm Inc (30 sec.)










1.2. What can you expect buying and holding a share of Celltrion Pharm Inc? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩9,205.52
Expected worth in 1 year
₩9,451.13
How sure are you?
85.0%

+ What do you gain per year?

Total Gains per Share
₩245.60
Return On Investment
0.4%

For what price can you sell your share?

Current Price per Share
₩59,800.00
Expected price per share
₩49,600 - ₩72,100
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Celltrion Pharm Inc (5 min.)




Live pricePrice per Share (EOD)
₩59,800.00

2.2. Growth of Celltrion Pharm Inc (5 min.)




Is Celltrion Pharm Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$266.6m$251.4m$12.2m4.6%

How much money is Celltrion Pharm Inc making?

Current yearPrevious yearGrowGrow %
Making money$2m$5.4m-$3.4m-173.2%
Net Profit Margin2.8%7.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Celltrion Pharm Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Celltrion Pharm Inc?

Welcome investor! Celltrion Pharm Inc's management wants to use your money to grow the business. In return you get a share of Celltrion Pharm Inc.

First you should know what it really means to hold a share of Celltrion Pharm Inc. And how you can make/lose money.

Speculation

The Price per Share of Celltrion Pharm Inc is ₩59,800. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Celltrion Pharm Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Celltrion Pharm Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩9,205.52. Based on the TTM, the Book Value Change Per Share is ₩61.40 per quarter. Based on the YOY, the Book Value Change Per Share is ₩174.40 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Celltrion Pharm Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.090.0%0.050.0%0.130.0%0.100.0%0.050.0%
Usd Book Value Change Per Share0.110.0%0.040.0%0.120.0%0.090.0%0.090.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.110.0%0.040.0%0.120.0%0.090.0%0.090.0%
Usd Price Per Share62.16-61.76-50.79-71.09-48.13-
Price to Earnings Ratio164.34-573.52-99.53-264.84-268.53-
Price-to-Total Gains Ratio575.77-307.13-593.77-1,925.92-1,190.33-
Price to Book Ratio9.65-9.69-8.35-12.97-9.07-
Price-to-Total Gains Ratio575.77-307.13-593.77-1,925.92-1,190.33-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share41.86
Number of shares23
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.040.09
Usd Total Gains Per Share0.040.09
Gains per Quarter (23 shares)0.992.10
Gains per Year (23 shares)3.958.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104-608-2
208-20176
3012202514
4016603422
50201004230
60241405138
70281805946
80322206754
90362607662
100403008470

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%34.05.01.085.0%39.05.02.084.8%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%34.06.00.085.0%40.06.00.087.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.046.00.0%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%34.06.00.085.0%40.06.00.087.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Celltrion Pharm Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--154.22961.400+151%174.397-12%130.739+18%126.131+22%
Book Value Per Share--9205.5239103.626+1%8680.881+6%7983.906+15%7384.853+25%
Current Ratio--1.5011.468+2%1.463+3%1.354+11%1.045+44%
Debt To Asset Ratio--0.4050.411-2%0.409-1%0.428-6%0.417-3%
Debt To Equity Ratio--0.6790.698-3%0.694-2%0.752-10%0.732-7%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--3416357289000.0003393679902819.345+1%2793894444104.225+22%3987179843916.603-14%2643441428723.165+29%
Eps--135.08969.427+95%189.658-29%140.802-4%72.884+85%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--7.2908.476-14%7.198+1%12.412-41%11.355-36%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.975+3%
Market Cap2474936620000.000-48%3675156720000.0003651359254569.345+1%3002619605346.725+22%4203150085368.603-13%2845866702041.415+29%
Net Profit Margin--0.0480.028+73%0.079-40%0.069-31%0.046+4%
Operating Margin----0%-0%0.030-100%0.024-100%
Operating Ratio--1.4951.561-4%1.264+18%1.020+47%0.967+55%
Pb Ratio6.496-48%9.6469.6910%8.350+16%12.966-26%9.072+6%
Pe Ratio110.668-48%164.336573.520-71%99.531+65%264.838-38%268.535-39%
Price Per Share59800.000-48%88800.00088225.000+1%72550.000+22%101557.500-13%68762.500+29%
Price To Free Cash Flow Ratio---18.606-100%986.963-100%223.356-100%108.310-100%
Price To Total Gains Ratio387.735-48%575.768307.132+87%593.775-3%1925.919-70%1190.328-52%
Quick Ratio---0.729-100%1.109-100%0.969-100%0.952-100%
Return On Assets--0.0090.004+95%0.013-32%0.010-13%0.005+65%
Return On Equity--0.0150.008+93%0.022-33%0.018-17%0.009+54%
Total Gains Per Share--154.22961.400+151%174.397-12%130.739+18%126.131+22%
Usd Book Value--266691654.600263739610.890+1%251492318.646+6%231300374.821+15%213945334.656+25%
Usd Book Value Change Per Share--0.1080.043+151%0.122-12%0.092+18%0.088+22%
Usd Book Value Per Share--6.4446.373+1%6.077+6%5.589+15%5.169+25%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--2391450102.3002375575931.974+1%1955726110.873+22%2791025890.742-14%1850409000.106+29%
Usd Eps--0.0950.049+95%0.133-29%0.099-4%0.051+85%
Usd Free Cash Flow---2388185.942-100%-780266.9740%3458125.613-100%-376437.8290%
Usd Market Cap1732455634.000-48%2572609704.0002555951478.199+1%2101833723.743+22%2942205059.758-13%1992106691.429+29%
Usd Price Per Share41.860-48%62.16061.758+1%50.785+22%71.090-13%48.134+29%
Usd Profit--3913641.2002011366.627+95%5494538.726-29%4079163.069-4%2111510.423+85%
Usd Revenue--82008189.90070465903.188+16%68625720.973+20%59974806.385+37%40134668.630+104%
Usd Total Gains Per Share--0.1080.043+151%0.122-12%0.092+18%0.088+22%
 EOD+3 -4MRQTTM+27 -4YOY+14 -165Y+15 -1710Y+25 -7

3.3 Fundamental Score

Let's check the fundamental score of Celltrion Pharm Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15110.668
Price to Book Ratio (EOD)Between0-16.496
Net Profit Margin (MRQ)Greater than00.048
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.000
Current Ratio (MRQ)Greater than11.501
Debt to Asset Ratio (MRQ)Less than10.405
Debt to Equity Ratio (MRQ)Less than10.679
Return on Equity (MRQ)Greater than0.150.015
Return on Assets (MRQ)Greater than0.050.009
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Celltrion Pharm Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.667
Ma 20Greater thanMa 5056,150.000
Ma 50Greater thanMa 10058,986.000
Ma 100Greater thanMa 20066,738.000
OpenGreater thanClose61,000.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Celltrion Pharm Inc

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea.

Fundamental data was last updated by Penke on 2024-12-09 20:33:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Celltrion Pharm Inc earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Celltrion Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 4.8% means that ₩0.05 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Celltrion Pharm Inc:

  • The MRQ is 4.8%. The company is making a profit. +1
  • The TTM is 2.8%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ4.8%TTM2.8%+2.0%
TTM2.8%YOY7.9%-5.2%
TTM2.8%5Y6.9%-4.1%
5Y6.9%10Y4.6%+2.3%
4.3.1.2. Return on Assets

Shows how efficient Celltrion Pharm Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Celltrion Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.9% Return on Assets means that Celltrion Pharm Inc generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Celltrion Pharm Inc:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.4%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.9%TTM0.4%+0.4%
TTM0.4%YOY1.3%-0.8%
TTM0.4%5Y1.0%-0.6%
5Y1.0%10Y0.5%+0.5%
4.3.1.3. Return on Equity

Shows how efficient Celltrion Pharm Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Celltrion Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.5% Return on Equity means Celltrion Pharm Inc generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Celltrion Pharm Inc:

  • The MRQ is 1.5%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.5%TTM0.8%+0.7%
TTM0.8%YOY2.2%-1.4%
TTM0.8%5Y1.8%-1.0%
5Y1.8%10Y0.9%+0.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Celltrion Pharm Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Celltrion Pharm Inc is operating .

  • Measures how much profit Celltrion Pharm Inc makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Celltrion Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Celltrion Pharm Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y3.0%-3.0%
5Y3.0%10Y2.4%+0.7%
4.3.2.2. Operating Ratio

Measures how efficient Celltrion Pharm Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.49 means that the operating costs are ₩1.49 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Celltrion Pharm Inc:

  • The MRQ is 1.495. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.561. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.495TTM1.561-0.067
TTM1.561YOY1.264+0.297
TTM1.5615Y1.020+0.541
5Y1.02010Y0.967+0.053
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Celltrion Pharm Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Celltrion Pharm Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.50 means the company has ₩1.50 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Celltrion Pharm Inc:

  • The MRQ is 1.501. The company is able to pay all its short-term debts. +1
  • The TTM is 1.468. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.501TTM1.468+0.032
TTM1.468YOY1.463+0.005
TTM1.4685Y1.354+0.115
5Y1.35410Y1.045+0.309
4.4.3.2. Quick Ratio

Measures if Celltrion Pharm Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Celltrion Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.00 means the company can pay off ₩0.00 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Celltrion Pharm Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.729-0.729
TTM0.729YOY1.109-0.380
TTM0.7295Y0.969-0.241
5Y0.96910Y0.952+0.017
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Celltrion Pharm Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Celltrion Pharm Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Celltrion Pharm Inc to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.40 means that Celltrion Pharm Inc assets are financed with 40.5% credit (debt) and the remaining percentage (100% - 40.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Celltrion Pharm Inc:

  • The MRQ is 0.405. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.411. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.405TTM0.411-0.007
TTM0.411YOY0.409+0.002
TTM0.4115Y0.428-0.017
5Y0.42810Y0.417+0.011
4.5.4.2. Debt to Equity Ratio

Measures if Celltrion Pharm Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Celltrion Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 67.9% means that company has ₩0.68 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Celltrion Pharm Inc:

  • The MRQ is 0.679. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.698. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.679TTM0.698-0.019
TTM0.698YOY0.694+0.005
TTM0.6985Y0.752-0.054
5Y0.75210Y0.732+0.020
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Celltrion Pharm Inc generates.

  • Above 15 is considered overpriced but always compare Celltrion Pharm Inc to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 164.34 means the investor is paying ₩164.34 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Celltrion Pharm Inc:

  • The EOD is 110.668. Based on the earnings, the company is expensive. -2
  • The MRQ is 164.336. Based on the earnings, the company is expensive. -2
  • The TTM is 573.520. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD110.668MRQ164.336-53.668
MRQ164.336TTM573.520-409.184
TTM573.520YOY99.531+473.989
TTM573.5205Y264.838+308.682
5Y264.83810Y268.535-3.697
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Celltrion Pharm Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM18.606-18.606
TTM18.606YOY986.963-968.357
TTM18.6065Y223.356-204.750
5Y223.35610Y108.310+115.046
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Celltrion Pharm Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 9.65 means the investor is paying ₩9.65 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Celltrion Pharm Inc:

  • The EOD is 6.496. Based on the equity, the company is overpriced. -1
  • The MRQ is 9.646. Based on the equity, the company is overpriced. -1
  • The TTM is 9.691. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.496MRQ9.646-3.150
MRQ9.646TTM9.691-0.045
TTM9.691YOY8.350+1.341
TTM9.6915Y12.966-3.275
5Y12.96610Y9.072+3.895
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets639,787,509
Total Liabilities258,799,431
Total Stockholder Equity380,988,078
 As reported
Total Liabilities 258,799,431
Total Stockholder Equity+ 380,988,078
Total Assets = 639,787,509

Assets

Total Assets639,787,509
Total Current Assets372,583,821
Long-term Assets267,203,688
Total Current Assets
Total Current Assets  (as reported)372,583,821
Total Current Assets  (calculated)0
+/- 372,583,821
Long-term Assets
Long-term Assets  (as reported)267,203,688
Long-term Assets  (calculated)0
+/- 267,203,688

Liabilities & Shareholders' Equity

Total Current Liabilities248,274,453
Long-term Liabilities10,524,978
Total Stockholder Equity380,988,078
Total Current Liabilities
Total Current Liabilities  (as reported)248,274,453
Total Current Liabilities  (calculated)0
+/- 248,274,453
Long-term Liabilities
Long-term Liabilities  (as reported)10,524,978
Long-term Liabilities  (calculated)0
+/- 10,524,978
Total Stockholder Equity
Total Stockholder Equity (as reported)380,988,078
Total Stockholder Equity (calculated)0
+/- 380,988,078
Other
Common Stock Shares Outstanding 41,375
Net Working Capital 124,309,368



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
328,751,195
340,718,063
344,561,609
361,353,572
363,285,107
377,067,442
383,644,036
411,164,710
438,022,828
446,441,984
467,785,431
466,771,901
470,030,574
477,413,357
484,425,062
510,022,345
500,806,350
507,709,354
513,348,188
519,619,474
491,898,661
495,299,674
451,042,679
452,444,115
445,917,610
460,663,328
455,474,726
470,980,396
486,940,244
501,373,591
527,832,431
548,074,598
572,898,703
562,685,355
597,864,314
637,884,365
610,583,790
594,652,229
595,299,907
599,724,549
616,871,275
621,743,586
641,777,371
641,643,568
635,995,018
639,787,509
639,787,509635,995,018641,643,568641,777,371621,743,586616,871,275599,724,549595,299,907594,652,229610,583,790637,884,365597,864,314562,685,355572,898,703548,074,598527,832,431501,373,591486,940,244470,980,396455,474,726460,663,328445,917,610452,444,115451,042,679495,299,674491,898,661519,619,474513,348,188507,709,354500,806,350510,022,345484,425,062477,413,357470,030,574466,771,901467,785,431446,441,984438,022,828411,164,710383,644,036377,067,442363,285,107361,353,572344,561,609340,718,063328,751,195
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
190,492,267
199,977,508
211,106,672
186,749,582
192,807,468
193,229,831
199,960,536
194,112,984
202,932,586
188,738,772
188,855,498
189,813,737
202,057,665
221,652,934
230,954,115
257,168,631
249,932,387
287,762,759
331,139,865
308,402,554
292,972,547
304,939,017
311,917,985
332,403,870
337,218,379
360,543,570
364,831,000
362,369,486
372,583,821
372,583,821362,369,486364,831,000360,543,570337,218,379332,403,870311,917,985304,939,017292,972,547308,402,554331,139,865287,762,759249,932,387257,168,631230,954,115221,652,934202,057,665189,813,737188,855,498188,738,772202,932,586194,112,984199,960,536193,229,831192,807,468186,749,582211,106,672199,977,508190,492,26700000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
501,354
1,331,304
5,637,883
6,231,575
1,573,970
2,420,395
9,117,683
3,770,488
9,407,435
2,243,874
10,764,154
20,794,675
15,029,758
13,825,069
25,747,837
25,627,598
39,987,378
61,066,628
80,186,076
0
0
0
31,390,934
32,754,287
28,163,544
8,902,010
19,710,550
29,358,796
0
029,358,79619,710,5508,902,01028,163,54432,754,28731,390,93400080,186,07661,066,62839,987,37825,627,59825,747,83713,825,06915,029,75820,794,67510,764,1542,243,8749,407,4353,770,4889,117,6832,420,3951,573,9706,231,5755,637,8831,331,304501,35400000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
333,000
306,000
315,000
24,000
33,000
1
0
0
0
0
0
0
0
11,000,000
4,000,000
9,000,000
5,000,000
6,975,000
7,975,000
14,677,100
14,677,100
9,702,100
12,702,100
11,000,000
15,499,965
12,500,559
17,422,962
18,422,962
0
018,422,96217,422,96212,500,55915,499,96511,000,00012,702,1009,702,10014,677,10014,677,1007,975,0006,975,0005,000,0009,000,0004,000,00011,000,0000000000133,00024,000315,000306,000333,00000000000000000000
       Net Receivables 
31,497,288
32,077,901
32,883,769
34,687,796
34,714,378
37,093,759
38,767,833
54,756,753
63,265,482
65,206,430
65,209,149
43,725,842
54,575,477
63,709,714
69,234,867
81,229,190
91,198,401
103,250,603
114,342,870
125,327,883
99,705,476
111,027,597
120,609,179
133,335,690
132,140,271
137,675,660
136,284,230
139,465,638
132,965,918
135,173,726
141,265,824
142,016,031
157,600,303
151,144,699
152,811,187
172,490,963
160,465,309
174,858,718
187,857,335
185,945,202
187,553,518
202,553,666
235,231,835
222,081,827
197,487,267
0
0197,487,267222,081,827235,231,835202,553,666187,553,518185,945,202187,857,335174,858,718160,465,309172,490,963152,811,187151,144,699157,600,303142,016,031141,265,824135,173,726132,965,918139,465,638136,284,230137,675,660132,140,271133,335,690120,609,179111,027,59799,705,476125,327,883114,342,870103,250,60391,198,40181,229,19069,234,86763,709,71454,575,47743,725,84265,209,14965,206,43063,265,48254,756,75338,767,83337,093,75934,714,37834,687,79632,883,76932,077,90131,497,288
       Other Current Assets 
5,628,607
8,616,521
6,946,444
6,489,491
7,049,901
6,996,950
7,613,342
8,315,908
9,354,067
9,544,811
11,293,373
14,640,202
4,913,157
3,752,091
4,894,497
13,815,039
5,197,443
6,254,038
6,810,798
14,497,245
16,801,425
17,690,110
16,601,434
14,441,971
20,131,456
16,215,841
0
2,284,755
2,170,798
4,093,462
5,240,792
3,326,236
4,430,886
0
0
0
0
0
4,975,000
4,975,000
4,975,000
4,953,000
4,950,000
0
0
0
0004,950,0004,953,0004,975,0004,975,0004,975,000000004,430,8863,326,2365,240,7924,093,4622,170,7982,284,755016,215,84120,131,45614,441,97116,601,43417,690,11016,801,42514,497,2456,810,7986,254,0385,197,44313,815,0394,894,4973,752,0914,913,15714,640,20211,293,3739,544,8119,354,0678,315,9087,613,3426,996,9507,049,9016,489,4916,946,4448,616,5215,628,607
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
287,806,564
284,467,405
284,525,206
281,233,801
276,812,568
273,625,532
267,203,688
267,203,688273,625,532276,812,568281,233,801284,525,206284,467,405287,806,564000000000000000000000000000000000000000
       Property Plant Equipment 
122,656,909
130,162,859
136,011,598
145,624,157
153,504,377
158,738,563
167,899,322
196,120,295
205,282,091
215,349,630
217,982,598
219,162,215
216,919,291
214,600,786
211,865,929
209,835,826
207,134,416
204,862,886
202,405,569
199,864,329
197,559,954
197,084,483
198,936,618
195,554,369
194,792,415
203,264,770
212,421,642
216,577,174
232,201,693
234,376,347
242,465,520
248,255,789
247,137,239
245,668,204
243,405,553
241,925,499
237,862,219
235,503,559
231,762,623
228,242,792
225,352,593
227,054,829
224,408,597
220,762,473
217,047,315
0
0217,047,315220,762,473224,408,597227,054,829225,352,593228,242,792231,762,623235,503,559237,862,219241,925,499243,405,553245,668,204247,137,239248,255,789242,465,520234,376,347232,201,693216,577,174212,421,642203,264,770194,792,415195,554,369198,936,618197,084,483197,559,954199,864,329202,405,569204,862,886207,134,416209,835,826211,865,929214,600,786216,919,291219,162,215217,982,598215,349,630205,282,091196,120,295167,899,322158,738,563153,504,377145,624,157136,011,598130,162,859122,656,909
       Goodwill 
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
32,912,453
0
032,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,45332,912,453
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,332,593
1,332,593
1,332,593
1,332,593
1,332,593
1,332,593
1,581,593
1,581,593
1,581,593
1,581,593
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,581,5931,581,5931,581,5931,581,5931,332,5931,332,5931,332,5931,332,5931,332,5931,332,59300000000000000000
       Intangible Assets 
34,951,842
34,909,232
35,007,737
34,681,040
34,656,205
34,609,885
34,754,965
34,743,871
34,719,478
34,898,518
35,679,467
35,729,641
35,631,626
35,526,947
35,165,015
35,073,764
34,945,876
34,928,061
34,923,486
34,822,778
34,710,594
1,685,589
2,231,406
2,105,520
1,970,878
1,945,052
3,186,270
3,449,600
3,625,480
4,483,301
4,953,373
5,138,621
5,248,752
5,592,397
6,386,332
6,517,284
7,068,965
7,719,170
7,891,904
8,411,301
8,424,552
8,208,658
8,246,182
6,379,535
6,157,794
0
06,157,7946,379,5358,246,1828,208,6588,424,5528,411,3017,891,9047,719,1707,068,9656,517,2846,386,3325,592,3975,248,7525,138,6214,953,3734,483,3013,625,4803,449,6003,186,2701,945,0521,970,8782,105,5202,231,4061,685,58934,710,59434,822,77834,923,48634,928,06134,945,87635,073,76435,165,01535,526,94735,631,62635,729,64135,679,46734,898,51834,719,47834,743,87134,754,96534,609,88534,656,20534,681,04035,007,73734,909,23234,951,842
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
-1
0
1
0
0
0
00010-11000000000000000000000000000000000000000
> Total Liabilities 
170,110,935
181,960,594
180,437,823
192,941,205
194,394,334
204,886,098
210,274,821
196,739,013
219,637,004
225,509,820
235,996,592
230,537,479
195,897,566
176,674,076
182,114,315
165,374,762
157,697,583
163,531,410
168,406,618
176,645,642
169,014,872
175,734,010
182,066,020
182,409,436
175,451,994
187,893,071
180,320,777
190,949,018
205,620,636
215,744,616
238,278,964
247,513,800
270,144,580
245,757,677
271,461,243
305,915,567
278,438,270
252,699,910
245,121,465
242,938,002
257,560,685
250,920,200
266,952,717
264,977,833
261,389,995
258,799,431
258,799,431261,389,995264,977,833266,952,717250,920,200257,560,685242,938,002245,121,465252,699,910278,438,270305,915,567271,461,243245,757,677270,144,580247,513,800238,278,964215,744,616205,620,636190,949,018180,320,777187,893,071175,451,994182,409,436182,066,020175,734,010169,014,872176,645,642168,406,618163,531,410157,697,583165,374,762182,114,315176,674,076195,897,566230,537,479235,996,592225,509,820219,637,004196,739,013210,274,821204,886,098194,394,334192,941,205180,437,823181,960,594170,110,935
   > Total Current Liabilities 
81,842,837
86,578,074
68,503,195
26,622,023
42,145,250
56,167,977
84,085,374
111,559,887
42,643,694
56,707,096
51,742,976
112,489,636
85,267,274
93,664,467
89,061,799
72,387,460
64,690,367
70,678,046
112,909,111
124,290,303
119,996,536
129,834,462
139,705,537
145,034,436
138,553,196
149,272,662
136,871,759
149,138,502
156,124,951
160,249,255
178,658,668
184,926,886
208,252,854
191,569,728
221,724,341
259,914,246
240,044,943
218,324,685
211,186,161
211,998,455
230,204,790
225,895,706
246,495,386
249,345,550
250,469,377
248,274,453
248,274,453250,469,377249,345,550246,495,386225,895,706230,204,790211,998,455211,186,161218,324,685240,044,943259,914,246221,724,341191,569,728208,252,854184,926,886178,658,668160,249,255156,124,951149,138,502136,871,759149,272,662138,553,196145,034,436139,705,537129,834,462119,996,536124,290,303112,909,11170,678,04664,690,36772,387,46089,061,79993,664,46785,267,274112,489,63651,742,97656,707,09642,643,694111,559,88784,085,37456,167,97742,145,25026,622,02368,503,19586,578,07481,842,837
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135,915,527
37,437,500
6,875,000
10,312,500
13,750,000
13,750,000
13,750,000
13,750,000
13,750,000
100,171,781
108,960,000
106,459,115
106,124,821
121,121,994
121,000,000
121,423,276
121,043,952
121,220,725
121,220,837
121,225,654
121,480,493
121,534,284
121,238,454
121,488,783
131,000,000
146,000,000
0
0
0
000146,000,000131,000,000121,488,783121,238,454121,534,284121,480,493121,225,654121,220,837121,220,725121,043,952121,423,276121,000,000121,121,994106,124,821106,459,115108,960,000100,171,78113,750,00013,750,00013,750,00013,750,00013,750,00010,312,5006,875,00037,437,500135,915,52700000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135,915,527
37,437,500
6,875,000
10,312,500
13,750,000
13,750,000
13,750,000
13,750,000
13,750,000
13,750,000
0
0
0
0
0
0
0
0
0
0
0
0
138,571,713
138,822,042
148,333,259
163,333,259
153,815,735
153,333,259
0
0153,333,259153,815,735163,333,259148,333,259138,822,042138,571,71300000000000013,750,00013,750,00013,750,00013,750,00013,750,00013,750,00010,312,5006,875,00037,437,500135,915,52700000000000000000
       Accounts payable 
37,874,468
37,528,671
37,862,864
936,448
1,282,078
1,195,177
1,490,780
863,948
1,644,498
1,667,258
1,625,598
2,237,946
1,202,570
861,523
1,876,823
12,765,416
12,406,180
13,566,085
14,258,616
13,168,585
13,492,303
15,845,555
11,853,889
12,376,384
15,064,587
8,792,417
4,736,731
6,809,694
7,815,133
12,622,334
14,873,444
21,612,713
33,171,540
0
0
0
0
0
0
38,072,970
59,477,697
42,137,917
48,023,981
59,276,677
62,076,671
0
062,076,67159,276,67748,023,98142,137,91759,477,69738,072,97000000033,171,54021,612,71314,873,44412,622,3347,815,1336,809,6944,736,7318,792,41715,064,58712,376,38411,853,88915,845,55513,492,30313,168,58514,258,61613,566,08512,406,18012,765,4161,876,823861,5231,202,5702,237,9461,625,5981,667,2581,644,498863,9481,490,7801,195,1771,282,078936,44837,862,86437,528,67137,874,468
       Other Current Liabilities 
20,860,458
22,177,242
6,321,277
6,319,389
6,117,438
5,594,357
8,073,039
26,442,616
26,363,372
26,589,562
25,869,456
8,428,690
4,810,482
7,253,758
6,737,083
9,889,824
6,510,427
10,196,434
12,058,069
14,998,110
8,002,705
8,624,795
9,511,642
18,420,810
9,758,008
12,936,879
16,780,382
17,787,560
26,272,220
25,933,834
27,053,674
26,272,827
37,419,939
0
0
0
0
0
0
0
0
0
-1
0
0
0
000-100000000037,419,93926,272,82727,053,67425,933,83426,272,22017,787,56016,780,38212,936,8799,758,00818,420,8109,511,6428,624,7958,002,70514,998,11012,058,06910,196,4346,510,4279,889,8246,737,0837,253,7584,810,4828,428,69025,869,45626,589,56226,363,37226,442,6168,073,0395,594,3576,117,4386,319,3896,321,27722,177,24220,860,458
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,939,547
27,355,896
25,024,495
20,457,331
15,632,282
10,920,617
10,524,978
10,524,97810,920,61715,632,28220,457,33125,024,49527,355,89630,939,547000000000000000000000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,449,018
38,810,516
46,495,685
52,495,360
56,620,296
57,850,599
56,081,387
48,275,838
43,833,599
39,398,055
34,990,162
30,583,327
26,191,874
21,822,998
18,122,537
15,715,077
10,721,853
0
0
0
00010,721,85315,715,07718,122,53721,822,99826,191,87430,583,32734,990,16239,398,05543,833,59948,275,83856,081,38757,850,59956,620,29652,495,36046,495,68538,810,51640,449,01800000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-135,915,527
-37,437,500
-6,875,000
-10,312,500
-13,750,000
-13,750,000
-13,750,000
-13,750,000
-13,750,000
-100,171,781
-108,960,000
-106,459,115
-106,124,821
-121,121,994
-121,000,000
-121,423,276
-121,043,952
-121,220,725
-121,220,837
-121,225,654
-121,480,493
-121,534,284
-120,779,368
-120,182,469
-125,504,288
-141,119,438
4,377,608
3,938,207
0
03,938,2074,377,608-141,119,438-125,504,288-120,182,469-120,779,368-121,534,284-121,480,493-121,225,654-121,220,837-121,220,725-121,043,952-121,423,276-121,000,000-121,121,994-106,124,821-106,459,115-108,960,000-100,171,781-13,750,000-13,750,000-13,750,000-13,750,000-13,750,000-10,312,500-6,875,000-37,437,500-135,915,52700000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
57,963,518
56,759,121
54,434,082
53,143,109
51,822,205
4,802,888
802,808
775,627
1,074,354
1,317,629
1,202,835
1,539,497
2,538,890
2,970,962
3,089,764
3,099,507
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000003,099,5073,089,7642,970,9622,538,8901,539,4971,202,8351,317,6291,074,354775,627802,8084,802,88851,822,20553,143,10954,434,08256,759,12157,963,51800000000000000000
> Total Stockholder Equity
158,640,260
158,757,470
164,123,786
168,412,367
168,890,773
172,181,344
173,369,215
214,425,697
218,385,824
220,932,165
231,788,839
236,234,422
274,133,008
300,739,282
302,310,747
344,647,583
343,108,767
344,177,944
344,941,570
342,973,833
322,883,789
319,565,664
268,976,659
270,034,679
270,465,616
272,770,257
275,153,949
280,031,378
281,319,608
285,628,975
289,553,467
300,560,797
302,754,122
316,927,678
326,403,071
331,968,799
332,145,520
341,952,319
350,178,441
356,786,547
359,310,590
370,823,385
374,824,654
376,665,735
374,605,022
380,988,078
380,988,078374,605,022376,665,735374,824,654370,823,385359,310,590356,786,547350,178,441341,952,319332,145,520331,968,799326,403,071316,927,678302,754,122300,560,797289,553,467285,628,975281,319,608280,031,378275,153,949272,770,257270,465,616270,034,679268,976,659319,565,664322,883,789342,973,833344,941,570344,177,944343,108,767344,647,583302,310,747300,739,282274,133,008236,234,422231,788,839220,932,165218,385,824214,425,697173,369,215172,181,344168,890,773168,412,367164,123,786158,757,470158,640,260
   Common Stock
7,069,309
7,069,309
7,197,689
7,197,689
7,197,689
7,197,689
7,197,689
9,444,880
9,917,096
10,007,857
10,429,086
10,429,086
12,560,456
13,719,339
13,730,369
15,827,676
16,618,904
16,621,452
16,621,452
16,669,899
17,012,246
17,022,246
17,024,254
17,032,952
17,032,952
17,037,931
263,548,944
17,044,553
17,897,856
17,903,397
17,905,001
17,905,318
18,263,378
266,402,894
266,491,813
266,559,100
267,153,437
267,955,196
268,107,799
268,323,925
269,352,168
270,100,518
270,126,175
0
0
0
000270,126,175270,100,518269,352,168268,323,925268,107,799267,955,196267,153,437266,559,100266,491,813266,402,89418,263,37817,905,31817,905,00117,903,39717,897,85617,044,553263,548,94417,037,93117,032,95217,032,95217,024,25417,022,24617,012,24616,669,89916,621,45216,621,45216,618,90415,827,67613,730,36913,719,33912,560,45610,429,08610,429,08610,007,8579,917,0969,444,8807,197,6897,197,6897,197,6897,197,6897,197,6897,069,3097,069,309
   Retained Earnings 
1,810,157
1,940,326
1,910,180
1,867,410
19,716,830
1,902,363
1,926,813
1,972,044
1,990,351
1,294,566
1,317,514
1,340,462
1,364,962
1,195,004
1,165,299
1,100,998
1,141,439
31,977,638
1,226,700
806,513
820,030
5,004,417
-45,724,477
-45,122,651
2,850,434
4,845,789
6,895,432
11,168,290
12,543,888
16,437,611
20,759,950
31,565,514
38,521,178
51,758,208
60,687,411
65,786,529
69,510,809
77,055,132
85,007,159
91,199,345
96,951,006
107,512,996
110,815,744
111,524,832
112,429,524
0
0112,429,524111,524,832110,815,744107,512,99696,951,00691,199,34585,007,15977,055,13269,510,80965,786,52960,687,41151,758,20838,521,17831,565,51420,759,95016,437,61112,543,88811,168,2906,895,4324,845,7892,850,434-45,122,651-45,724,4775,004,417820,030806,5131,226,70031,977,6381,141,4391,100,9981,165,2991,195,0041,364,9621,340,4621,317,5141,294,5661,990,3511,972,0441,926,8131,902,36319,716,8301,867,4101,910,1801,940,3261,810,157
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,511,085
1,617,788
1,739,536
1,847,205
2,058,327
2,243,016
2,342,352
2,479,252
2,936,523
3,335,846
0
0
0
0
0
0
0
0
0
0
00000000003,335,8462,936,5232,479,2522,342,3522,243,0162,058,3271,847,2051,739,5361,617,7881,511,08500000000000000000000000000
   Treasury Stock0000000000-7,572,130-7,572,130-7,572,130-7,572,130-2,337,484-2,337,484-2,337,484-2,337,484-1,233,456-1,233,456000-1,233,456-1,233,456-1,233,456-202,722-202,722-202,721-101,139-101,139-101,139-101,139-52,097-52,097-52,097-52,097-52,097-13,670-13,670-13,670-13,670-13,670-13,670-13,670-13,670
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,449,922
1,507,634
1,075,170
1,087,972
1,263,780
1,348,268
1,557,589
4,426,145
1,857,511
3,955,387
2,592,214
2,715,760
2,823,365
2,338,521
2,519,599
2,619,851
3,581,957
3,955,386
3,955,386
3,955,386
5,280,957
4,894,713
4,799,652
4,478,443
4,150,654
4,029,414
0
0
0
0004,029,4144,150,6544,478,4434,799,6524,894,7135,280,9573,955,3863,955,3863,955,3863,581,9572,619,8512,519,5992,338,5212,823,3652,715,7602,592,2143,955,3871,857,5114,426,1451,557,5891,348,2681,263,7801,087,9721,075,1701,507,6341,449,92200000000000000000



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue388,794,335
Cost of Revenue-269,084,130
Gross Profit119,710,205119,710,205
 
Operating Income (+$)
Gross Profit119,710,205
Operating Expense-352,723,619
Operating Income36,070,716-233,013,414
 
Operating Expense (+$)
Research Development12,707,344
Selling General Administrative35,175,842
Selling And Marketing Expenses0
Operating Expense352,723,61947,883,186
 
Net Interest Income (+$)
Interest Income1,316,692
Interest Expense-8,290,134
Other Finance Cost-0
Net Interest Income-6,973,442
 
Pretax Income (+$)
Operating Income36,070,716
Net Interest Income-6,973,442
Other Non-Operating Income Expenses0
Income Before Tax (EBT)26,208,87036,070,716
EBIT - interestExpense = -8,290,134
21,264,989
29,555,123
Interest Expense8,290,134
Earnings Before Interest and Taxes (EBIT)034,499,004
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax26,208,870
Tax Provision-4,943,881
Net Income From Continuing Ops21,264,98921,264,989
Net Income21,264,989
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net06,973,442
 

Technical Analysis of Celltrion Pharm Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Celltrion Pharm Inc. The general trend of Celltrion Pharm Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Celltrion Pharm Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Celltrion Pharm Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 64,100 < 67,400 < 72,100.

The bearish price targets are: 49,600 > 49,600.

Tweet this
Celltrion Pharm Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Celltrion Pharm Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Celltrion Pharm Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Celltrion Pharm Inc. The current macd is 558.90.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Celltrion Pharm Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Celltrion Pharm Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Celltrion Pharm Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Celltrion Pharm Inc Daily Moving Average Convergence/Divergence (MACD) ChartCelltrion Pharm Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Celltrion Pharm Inc. The current adx is 26.53.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Celltrion Pharm Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Celltrion Pharm Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Celltrion Pharm Inc. The current sar is 52,969.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Celltrion Pharm Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Celltrion Pharm Inc. The current rsi is 54.67. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Celltrion Pharm Inc Daily Relative Strength Index (RSI) ChartCelltrion Pharm Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Celltrion Pharm Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Celltrion Pharm Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Celltrion Pharm Inc Daily Stochastic Oscillator ChartCelltrion Pharm Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Celltrion Pharm Inc. The current cci is 89.70.

Celltrion Pharm Inc Daily Commodity Channel Index (CCI) ChartCelltrion Pharm Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Celltrion Pharm Inc. The current cmo is 14.50.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Celltrion Pharm Inc Daily Chande Momentum Oscillator (CMO) ChartCelltrion Pharm Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Celltrion Pharm Inc. The current willr is -31.08108108.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Celltrion Pharm Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Celltrion Pharm Inc Daily Williams %R ChartCelltrion Pharm Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Celltrion Pharm Inc.

Celltrion Pharm Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Celltrion Pharm Inc. The current atr is 2,837.

Celltrion Pharm Inc Daily Average True Range (ATR) ChartCelltrion Pharm Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Celltrion Pharm Inc. The current obv is 25,274,951.

Celltrion Pharm Inc Daily On-Balance Volume (OBV) ChartCelltrion Pharm Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Celltrion Pharm Inc. The current mfi is 62.17.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Celltrion Pharm Inc Daily Money Flow Index (MFI) ChartCelltrion Pharm Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Celltrion Pharm Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-07-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-31STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-30RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-12ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

Celltrion Pharm Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Celltrion Pharm Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5054.667
Ma 20Greater thanMa 5056,150.000
Ma 50Greater thanMa 10058,986.000
Ma 100Greater thanMa 20066,738.000
OpenGreater thanClose61,000.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Celltrion Pharm Inc with someone you think should read this too:
  • Are you bullish or bearish on Celltrion Pharm Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Celltrion Pharm Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Celltrion Pharm Inc

I send you an email if I find something interesting about Celltrion Pharm Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Celltrion Pharm Inc.

Receive notifications about Celltrion Pharm Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.